156 related articles for article (PubMed ID: 19424641)
1. DMAT, an inhibitor of protein kinase CK2 induces reactive oxygen species and DNA double strand breaks.
Schneider CC; Hessenauer A; Götz C; Montenarh M
Oncol Rep; 2009 Jun; 21(6):1593-7. PubMed ID: 19424641
[TBL] [Abstract][Full Text] [Related]
2. 2-Dimethylamino-4,5,6,7-tetrabromo-1H-benzimidazole: a novel powerful and selective inhibitor of protein kinase CK2.
Pagano MA; Meggio F; Ruzzene M; Andrzejewska M; Kazimierczuk Z; Pinna LA
Biochem Biophys Res Commun; 2004 Sep; 321(4):1040-4. PubMed ID: 15358133
[TBL] [Abstract][Full Text] [Related]
3. The selectivity of inhibitors of protein kinase CK2: an update.
Pagano MA; Bain J; Kazimierczuk Z; Sarno S; Ruzzene M; Di Maira G; Elliott M; Orzeszko A; Cozza G; Meggio F; Pinna LA
Biochem J; 2008 Nov; 415(3):353-65. PubMed ID: 18588507
[TBL] [Abstract][Full Text] [Related]
4. Selectivity analysis of protein kinase CK2 inhibitors DMAT, TBB and resorufin in cisplatin-induced stress responses.
Fritz G; Issinger OG; Olsen BB
Int J Oncol; 2009 Nov; 35(5):1151-7. PubMed ID: 19787270
[TBL] [Abstract][Full Text] [Related]
5. Novel small molecule protein kinase CK2 inhibitors exert potent antitumor effects on T98G and SEGA cells in vitro.
Pucko E; Ostrowski R; Matyja E
Folia Neuropathol; 2019; 57(3):239-248. PubMed ID: 31588710
[TBL] [Abstract][Full Text] [Related]
6. Quinone reductase 2 is an adventitious target of protein kinase CK2 inhibitors TBBz (TBI) and DMAT.
Leung KK; Shilton BH
Biochemistry; 2015 Jan; 54(1):47-59. PubMed ID: 25379648
[TBL] [Abstract][Full Text] [Related]
7. Development and exploitation of CK2 inhibitors.
Sarno S; Ruzzene M; Frascella P; Pagano MA; Meggio F; Zambon A; Mazzorana M; Di Maira G; Lucchini V; Pinna LA
Mol Cell Biochem; 2005 Jun; 274(1-2):69-76. PubMed ID: 16335530
[TBL] [Abstract][Full Text] [Related]
8. An unbiased evaluation of CK2 inhibitors by chemoproteomics: characterization of inhibitor effects on CK2 and identification of novel inhibitor targets.
Duncan JS; Gyenis L; Lenehan J; Bretner M; Graves LM; Haystead TA; Litchfield DW
Mol Cell Proteomics; 2008 Jun; 7(6):1077-88. PubMed ID: 18258654
[TBL] [Abstract][Full Text] [Related]
9. Multitarget Anticancer Agents Based on Histone Deacetylase and Protein Kinase CK2 inhibitors.
Martínez R; Geronimo BD; Pastor M; Zapico JM; Coderch C; Panchuk R; Skorokhyd N; Maslyk M; Ramos A; de Pascual-Teresa B
Molecules; 2020 Mar; 25(7):. PubMed ID: 32218358
[TBL] [Abstract][Full Text] [Related]
10. Induction of cell death in antiestrogen resistant human breast cancer cells by the protein kinase CK2 inhibitor DMAT.
Yde CW; Frogne T; Lykkesfeldt AE; Fichtner I; Issinger OG; Stenvang J
Cancer Lett; 2007 Oct; 256(2):229-37. PubMed ID: 17629615
[TBL] [Abstract][Full Text] [Related]
11. A specific inhibitor of protein kinase CK2 delays gamma-H2Ax foci removal and reduces clonogenic survival of irradiated mammalian cells.
Zwicker F; Ebert M; Huber PE; Debus J; Weber KJ
Radiat Oncol; 2011 Feb; 6():15. PubMed ID: 21310046
[TBL] [Abstract][Full Text] [Related]
12. New inhibitors of protein kinase CK2, analogues of benzimidazole and benzotriazole.
Bretner M; Najda-Bernatowicz A; Łebska M; Muszyńska G; Kilanowicz A; Sapota A
Mol Cell Biochem; 2008 Sep; 316(1-2):87-9. PubMed ID: 18548199
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of experimental HCC growth in mice by use of the kinase inhibitor DMAT.
Sass G; Klinger N; Sirma H; Hashemolhosseini S; Hellerbrand C; Neureiter D; Wege H; Ocker M; Tiegs G
Int J Oncol; 2011 Aug; 39(2):433-42. PubMed ID: 21567083
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and mechanism of anti-tumor action of new potential CK2 inhibitors toward glioblastoma cells.
Kaminska B; Ellert-Miklaszewska A; Oberbek A; Wisniewski P; Kaza B; Makowska M; Bretner M; Kazimierczuk Z
Int J Oncol; 2009 Nov; 35(5):1091-100. PubMed ID: 19787263
[TBL] [Abstract][Full Text] [Related]
15. Anti-neoplastic effect of protein kinase CK2 inhibitor, 2-dimethylamino-4,5,6,7-tetrabromobenzimidazole (DMAT), on growth and hormonal activity of human adrenocortical carcinoma cell line (H295R) in vitro.
Lawnicka H; Kowalewicz-Kulbat M; Sicinska P; Kazimierczuk Z; Grieb P; Stepien H
Cell Tissue Res; 2010 May; 340(2):371-9. PubMed ID: 20383646
[TBL] [Abstract][Full Text] [Related]
16. Synergistic anti-leukemic effects of CK2 inhibitors and pentabromobenzylisothioureas in vitro.
Koronkiewicz M; Chilmonczyk Z; Kazimierczuk Z
Anticancer Res; 2013 Nov; 33(11):4891-9. PubMed ID: 24222126
[TBL] [Abstract][Full Text] [Related]
17. Synthesis of novel polybrominated benzimidazole derivatives-potential CK2 inhibitors with anticancer and proapoptotic activity.
Łukowska-Chojnacka E; Wińska P; Wielechowska M; Poprzeczko M; Bretner M
Bioorg Med Chem; 2016 Feb; 24(4):735-41. PubMed ID: 26778657
[TBL] [Abstract][Full Text] [Related]
18. p53 is dispensable for the induction of apoptosis after inhibition of protein kinase CK2.
Schneider CC; Hessenauer A; Montenarh M; Götz C
Prostate; 2010 Feb; 70(2):126-34. PubMed ID: 19760628
[TBL] [Abstract][Full Text] [Related]
19. Role of protein kinase CK2 in the regulation of tumor necrosis factor-related apoptosis inducing ligand-induced apoptosis in prostate cancer cells.
Wang G; Ahmad KA; Ahmed K
Cancer Res; 2006 Feb; 66(4):2242-9. PubMed ID: 16489027
[TBL] [Abstract][Full Text] [Related]
20. Quinalizarin as a potent, selective and cell-permeable inhibitor of protein kinase CK2.
Cozza G; Mazzorana M; Papinutto E; Bain J; Elliott M; di Maira G; Gianoncelli A; Pagano MA; Sarno S; Ruzzene M; Battistutta R; Meggio F; Moro S; Zagotto G; Pinna LA
Biochem J; 2009 Jul; 421(3):387-95. PubMed ID: 19432557
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
